Immatics may develop T-Cell
Receptor Engineered T-cell
Therapy (TCR-T) programs against solid tumor targets discovered with Immatics' XPRESIDENT technology.
If Immatics develops programs against T-cell
receptor engineered T-cell
, or TCR-T, targets, it will be responsible for the development and validation of these programs through the lead candidate stage, per the deal.
[ClickPress, Wed Aug 21 2019] This report analyzes the current and future scenario of the global T-cell
Acute Lymphoblastic Leukemia Market .
Immunotherapies Market (4th Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.
How CAR T-cell
therapy works CAR T-cell
is a complex immunotherapy treatment.
In the study, researchers examined the mechanisms underlying the expansion of myeloid-derived suppressor cells (MDSCs) and the suppression of T-cell
responses in persistent HBV infection.
- The US Food and Drug Administration has granted orphan drug designation to US-based biopharmaceutical company Imbrium Therapeutics L.P.'s investigational drug tinostamustine, a potentially first-in-class alkylating deacetylase inhibiting molecule being studied in early phase clinical trials, for the treatment of T-cell
prolymphocytic leukemia (T-PLL), the company said.
To boost the immune system's ability to recognize and attack these "invaders," researchers may transfer genes for a tumor-specific T-cell
receptor into the T cells collected from a patient's transplant donor.
Food and Drug Administration (FDA) has cleared Eureka Therapeutics investigational new drug (IND) application for ET140202 ARTEMIS T-cell
therapy in AFP- positive patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer.
M2 EQUITYBITES-February 1, 2019-USFDA approves Eureka Therapeutics investigational new drug for ET140202 ARTEMIS T-cell
lineage lymphomas also occur in GI locations, however, and some are related to underlying GI diseases or treatment.